These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...

LOE risks are mitigated by delayed Vyndamax generic entry to mid-2031, supporting the management’s high single-digit 5Y ...

In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...

A rare hantavirus outbreak on an Atlantic cruise ship has reignited conspiratorial Covid-era misinformation, with posts ...

Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched ...

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc. (NYSE:PFE) ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

The registrar ultimately concluded that the competing trademarks were “overall, dissimilar”. Read more at straitstimes.com.

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...